Myocardial Infarction and Stroke Risk in Young Healthy Men Treated with Injectable Testosterone

Table 3

Characteristics of study population from Low Testosterone (T) Centers.

		Percent
Patients on testosterone therapy	19,968	100%
Gender
All male	19,968	100%
Age
>55 years	3,833	19.2%
45–54 years	7,008	35.1%
35–44 years	6,829	34.2%
<34 years	2,296	11.5%
Prevalence of DM	798	4%
Prevalence of HTN	2,995	15%
Prevalence of HLD	2,396	12%
Mean age (years)	46.10	N/A
Drug
Testosterone cypionate	18,742	93.8%
AndroGel	540	2.7%
Testim	326	1.6%
Fortesta	47	0.2%
Axiron	230	1%
Striant	9	0.04%
Others	74	0.66%
Hematocrit >52%	13,178	66%
Hematocrit ≤52%	8,785	44%
	Mean	Range
Time of exposure to testosterone (months)	24.7	0–60 month
Total testosterone level on treatment (ng/dL)	543 (SEM = 1.53)	50–1600
Calculated free testosterone on treatment (ng/mL)	13.08 (SEM = 0.48)	3.29–28.2
Estradiol level while on treatment (pg/dL)	31.1	6.4–453
PSA while on treatment (ng/mL)	1.22	0.02–109